Lung cancer is the most common cause of cancer death in both males and females in the United States and is projected to cause an estimated 161,840 deaths in 2008 ( 1 ) . Cigarette smoking is the primary risk factor for lung cancer and is associated with approximately 87% of all patients ( 2 ) . Histologically, lung cancer is classifi ed into two broad categories: small cell carcinoma and non -small cell carcinoma (which includes squamous cell carcinoma, adenocarcinoma, large cell carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma, and carcinoid tumor histological types). In clinical practice, it is not uncommon to encounter patients with multiple anatomically separate but histologically similar lung tumors. The incidence of this condition, also referred to as multifocality, has been reported to range from 0.2% to 2.0% in patients with primary lung cancer ( 3 -5 ) .
Coexisting lung cancers in a patient can be characterized as either synchronous (detected or resected simultaneously) or metachronous (defi ned by a time interval between detection of the fi rst lesion and of a subsequent lesion). Metachronous lung cancers are likely more common, representing 50% -70% of all patients with multiple coexisting lung cancers ( 3 , 6 , 7 ) . Two different theories have been proposed to explain the multifocality of lung tumors. The fi rst is that these tumors are of monoclonal origin, arising from a single malignant cell that forms a neoplasm, which
Background
Lung cancer is the most common cause of cancer death in the United States. Multiple anatomically separate but histologically similar lung tumors are often found in the same patient. The clonal origin of multiple lung tumors is uncertain.
Methods
We analyzed 70 lung tumors from 30 patients (23 females and seven males) who underwent surgical resection for lung epithelial tumors, of whom 26 had non -small cell carcinomas and four had carcinoid/ atypical carcinoid tumors. All patients had multiple tumors (two to five) involving one or both lungs. Genomic DNA was extracted from paraffin-embedded tissue sections using laser capture microdissection and analyzed for loss of heterozygosity, TP53 mutations, and X-chromosome inactivation status. The percentage (95% confidence interval [CI] ) of patients in whom there were concordant patterns of genetic alteration was calculated.
Results
All 30 case subjects showed loss of heterozygosity (LOH) in at least one and at most four of the six polymorphic microsatellite markers. Completely concordant LOH patterns between synchronous and metachronous cancers in individual patients were seen in 26 (87%) of 30 informative patients (95% CI = 75% to 99%). Identical point mutations were present in eight of 10 patients who exhibited TP53 mutation by sequencing. Tumors in 18 (78%) of 23 female patients (95% CI = 67% to 98%) showed identical X-chromosome inactivation patterns. Combining the results of LOH studies, TP53 mutation screening analyses, and X-chromosome inactivation data, we demonstrated that the multiple separate tumors in 23 (77%) of 30 patients (95% CI = 62% to 92%) had identical genetic changes, consistent with monoclonal origin of the separate tumors.
Conclusions
Our data indicate that the great majority of multifocal lung cancers have a common clonal origin and that multifocality in lung cancer represents local and regional intrapulmonary metastasis. metastasizes to other regions of the lung parenchyma. The second is that multifocal tumors arise separately from anatomically distinct malignant progenitor cells that independently undergo different genetic alterations, leading to neoplastic transformation ( 8 ) . Supporting the latter view is the study of Sikkink et al. ( 9 ) , who evaluated the entire bronchial tree surrounding a primary bronchial squamous cell carcinoma and observed allele-specifi c imbalances and widespread genetic changes in the whole lung. These investigators proposed that multifocality represents clonal expansion of multiple separate primary neoplasms arising from a background of fi eld cancerization ( 9 ) . Distinguishing between these two possible mechanisms for the development of multifocal lesions has important surgical, therapeutic, and prognostic implications.
Molecular analysis of microsatellite markers is a method that has been used to assess clonality ( 10 ) . Microsatellite markers are highly polymorphic short tandem repeats of DNA sequences. Loss of heterozygosity (LOH) of a given microsatellite marker may imply the loss of a potential tumor suppressor gene at the chromosome segment. Therefore, LOH studies are useful not only for assessing clonality but also for analyzing the molecular changes involved in carcinogenesis. In contrast, X-chromosome inactivation (methylation) studies from female patients can be used specifically to evaluate clonality. They do not provide information concerning precise genetic pathways involved in carcinogenesis.
Because frequent LOH in regions of chromosomes 3p, 4q, 9p, 11q, and 17p as well as TP53 gene mutation have been observed in lung cancers ( 11 -21 ) , we investigated the clonality of multiple coexisting lung tumors by sequencing TP53 gene mutations and by analyzing LOH using a panel of six polymorphic microsatellite markers at chromosome positions 3p14 -21 (D3S1766), 4q33 -34 (D4S408), 9p21 (IFNA, D9S171), 11q13 (D11S970), and 17p13.1 ( TP53 ). We also examined the X-chromosome inactivation status of the separate tumors in female patients. We postulated that the extent of correlation of allelic loss, TP53 gene mutation status, and X-chromosome inactivation in multifocal cancers would be indicative of whether these tumors represent multicentric independent primary lesions or whether they are derived from the same malignant progenitor cell.
Materials and Methods

Patients
All patients underwent surgical resections for lung tumors between January 1, 1996, and December 31, 2006. Although multiple primary lung cancers are more common in men than in women, we included 23 female patients in this study to evaluate clonality by X-chromosome inactivation analysis. The tumors were retrieved from the surgical pathology archives of participating institutions. The medical records and pathological findings were reviewed. Formalin-fixed, paraffin-embedded tissue was available for all patients. All patients had multiple tumors (two to five) involving one or both lungs. In each individual patient, multiple tumors of the same histological type were identified. All patients were staged according to the 2002 American Joint Committee on Cancer (AJCC) TNM staging system ( 22 ) . This study was approved by the institutional review boards, and appropriate written informed consent was obtained from all patients.
Tissue Samples and Microdissection
Histological sections were prepared from formalin-fixed, paraffinembedded tissue and were stained with hematoxylin and eosin for microscopic evaluation. Laser-assisted microdissection of the tumor tissues was performed on the lightly stained sections with a PixCell II Laser Capture Microdissection system (Arcturus Engineering, Mountain View, CA) ( 23 -25 ) . Approximately 600 -1000 cells of each tumor were microdissected from the 5-µ m histological sections ( Figure 1 ). Normal tissue microdissected from the same patient was used as a control. The dissected tissue was incubated overnight in 50 µ L of digesting buffer containing 10 mM Tris -HCl, 1 mM EDTA, 1% Tween 20, and proteinase K at 5 mg/mL (pH 8.3) at 37°C.
LOH Analysis
Polymerase chain reaction (PCR) was used to amplify genomic DNA from both normal and tumor cells. A panel of six polymorphic microsatellite markers on chromosome 3p14 -21 (D3S1766), 4q33 -34 (D4S408), 9p21 (IFNA, D9S171), 11q13 (D11S970), and 17p13.1 ( TP53 ) was chosen because previous studies had shown that LOH frequently occurs at these loci in lung cancers ( 11 -21 ) . The sequences of the primers flanking six microsatellite markers were obtained from the Genome Database. PCR amplification and gel electrophoresis were done as previously described ( 26 , 27 ) . PCRs for each polymorphic microsatellite marker were repeated at least twice from the same DNA preparations, and the same results were obtained. The criteria for LOH were complete or nearly complete absence of one allele ( ≥ 75% loss) in tumor DNA ( 28 , 29 ) .
CONTEXT AND CAVEATS
Prior knowledge
Whether multifocal lung cancers arise from a single transformed cell whose progeny metastasize to different locations in the lung or occur independently via independent processes leading to transformation of distinct cells at different locations was unknown.
Study design
Three different methods were used to assess the genetic similarity of distinct tumors from a single patient and thus whether they arose from a single cell.
Contribution
The concordance of genetic changes in the separate tumors made a strong case for monoclonality of most multifocal lung cancers.
Implications
The finding suggest that the majority of multifocal malignant tumors do not arise from entirely independent mutational events in separate cells; more study will be required to determine if they arise from a single transformed cell, followed by replication and subsequent metastasis.
Limitations
The tumors analyzed were predominantly adenocarcinomas, so the results do not necessarily apply to all lung cancer types.
From the Editors
When the control DNA for normal lung tissue was found to be homozygous for the polymorphic markers (ie, showing only one allele in the normal control tissue), the patient was considered noninformative ( 28 ) . When the control DNA was found to be heterozygous for the polymorphic markers (ie, showing two different alleles in the normal control tissue), the patient was considered informative. Informative patients were divided into two categories: no LOH meant that the patient ' s DNA showed no allelic deletions in the tumor (ie, retaining two different alleles of similar intensity) and LOH meant that the patient's DNA showed absence of one allele in the tumor. Tumors from the same patient that demonstrated identical allelic loss patterns were considered to have a common clonal origin, whereas different patterns of allelic deletions were considered to represent tumors of independent clonal origins ( 26 , 27 , 30 -34 ) ( Figure 2 ).
TP53 Gene Mutation Analysis by DNA Sequencing
Because most TP53 gene mutations are point mutations located in the region between exons 5 and 8, an area that encompasses the DNA-binding site of the p53 protein, exons 5, 7, and 8 of TP53 gene were screened for mutations by direct DNA sequencing. DNA fragments were amplified by PCR using forward and reverse primers ( 35 , 36 ) . DNA sequencing was carried out directly on PCR-amplified, double-stranded DNA by use of the dideoxynucleotide chain termination method on an automated sequencer and a PCR-product sequencing kit. The diagnosis of different clonality was made when different mutations were found in two or more tumor samples from one patient. Tumors were considered to have the same clonality when they showed identical DNA mutations and the normal lung control tissue showed no evidence of the mutation(s) ( Figure 1 ) . 
X-chromosome Inactivation Analysis
The X-chromosome -linked human androgen receptor ( AR ) gene locus was chosen for X-chromosome inactivation study. The analysis was performed on all of the tumors from the 23 female patients as previously described ( 25 , 28 , 30 , 37 -39 ) . Our analysis was based on a highly polymorphic CAG repeat in exon 1 of the human androgen receptor gene on chromosome Xq11 -12 ( 10 ) . This polymorphic marker is near the methylation-sensitive site of the Hha I restriction endonuclease. In the general population, the frequency of genetic polymorphism for this marker is greater than 90% ( 37 , 38 ) . Inactivated X chromosomes in this assay are identified because the endonuclease Hha I is unable to cut the DNA if the cytosine in the recognition site is methylated on the 5 ′ position of the pyrimidine ring.
DNA samples were prepared from each tumor. Eight-microliter aliquots of the DNA extract were digested for 2 hours with 1 U of Hha I (New England Biolabs, Inc., Beverly, MA) in a total volume of 10 µ L. Control reactions for each sample were incubated in the digestion buffer without Hha I. After incubation, 3 µ L of digested or undigested DNA was amplifi ed in a 25-µ L PCR mixture containing 0.1 µ L of ␣ -32 P -labeled deoxyadenosine triphosphate (3000 Ci/mmol), AR-sense and AR-antisense primers (each at 4 µ mol/L), 4% dimethyl sulfoxide, MgCl 2 at 2.5 mmol/L, all four deoxynucleoside triphosphates (each at 300 µ mol/L), and 0.5 U of Taq DNA polymerase (Perkins -Elmer Cetus, Foster City, CA). Primers used in the reaction were as follows: AR-sense, 5 ′ -TCC AGA ATC TGT TCC AGA GCG TGC-3 ′ , and AR-antisense, 5 ′ -GCT GTG AAG GTT GCT GTT CCT CAT-3 ′ . PCR amplifi cation was performed with an initial denaturation step of 95°C for 5 minutes, followed by 38 cycles of 95°C for 40 seconds, 63°C for 40 seconds, and 72°C for 60 seconds; the fi nal extension step was at 72°C for 7 minutes. The PCR products were then diluted with 4 µ L of loading buffer containing 95% deionized formamide, EDTA at 20 mmol/L, 0.05% bromophenol, and 0.05% xylene cyanole FF (Sigma Chemical Co., St Louis, MO). The samples were heated to 95°C for 5 minutes and then placed on ice. Three microliters of this mixture was loaded onto 6.5% denaturing polyacrylamide gels without formamide. Electrophoresis was performed at 80 W for 3 hours, followed by autoradiography with Biomax MS fi lm (Kodak Company, Rochester, NY) for 8 -18 hours.
The patient was considered to be informative if two AR allele bands were detected after PCR amplifi cation in normal control samples that had not been treated with Hha I. Only informative patients were included in the analysis. In tumor samples, nonrandom X-chromosome inactivation was defi ned as a complete or a nearly complete absence of a band corresponding to an AR allele after Hha I digestion, which indicated a predominance of one allele-specifi c modifi cation in the tumor. Tumors were considered to be of the same clonal origin if the same AR allelic inactivation pattern was detected in each tumor from the same patient. Tumors were considered to be of independent origin if alternate AR allele predominates after Hha I digestion (different allelic inactivation patterns) was detected in each tumor ( 37 , 38 , 40 ) .
Statistical Methods
We compared each allelic loss status (loss of upper allele, loss of lower allele, and no loss) of separate tumor samples from the same patient. We calculated the percentage of concordant mutation in the separate tumor samples from the same patient. A discordant pattern would suggest a different clonal origin, whereas a concordant allelic pattern is compatible with monoclonal origin. The 95% confidence interval (CI) of patients in whom there was concordant patterns of genetic alterations was calculated in all patients.
Results
Thirty patients (23 females and seven males) with a total of 70 separate tumors were included in this study ( Table 1 ) . Their ages ranged from 30 to 80 years (mean = 59 years). Eighteen patients had synchronous tumors, and 12 patients had metachronous tumors. The time interval between detection of the metachronous lesions and of the primary resection ranged from 3 months to 3 years. In each individual patient, multiple tumors of the same histological type were identified. Adenocarcinoma was found in 19 patients for a total of 42 tumors, six patients had squamous cell carcinoma (15 tumors), one patient had large cell carcinoma (two tumors), and four patients had carcinoid tumors (11 tumors). Tumor sizes ranged from 0.3 to 7.0 cm. In the 12 patients who developed metachronous tumors, the metachronous lesion arose in a different lung lobe (whether they had adenocarcinoma [eight patients], squamous cell carcinoma [three patients], or large cell carcinoma [one patient]). Of the patients with synchronous tumors, four had carcinoid tumors in the same lung lobe and five had either discrete adenocarcinomas or squamous cell carcinomas in different lung lobes (three and two patients, respectively). Nine patients had multiple adenocarcinomas (eight patients) or squamous cell carcinomas (one patient) involving a single lung lobe. The pathological stage conforming to the 2002 AJCC TNM staging system was T1 -T3 for 16 patients and T4 for 14 patients.
We analyzed a total of 70 separate tumors from 30 patients (23 females and seven males) for six polymorphic DNA markers and determined whether there was X-chromosome inactivation in 52 tumors from female patients ( Table 2 and Figure 3 ) . Among the 30 patients, the informative rates (%) for the polymorphic markers were as follows: 90% (27 patients) at D3S1766 (3p14 -21), 93% (28 patients) at D4S408 (4q33 -34), 100% (30 patients) at IFNA (9p21), 90% (27 patients) at D9S171 (9p21), 87% (26 patients) at D11S970 (11q13), and 90% (27 patients) at TP53 (17p13.1). After excluding noninformative patients, the overall frequencies of allelic loss for each locus were 41% (ie, 25 A total of 41 tumors from 18 patients were screened for mutations in TP53 gene exons 5, 7, and 8 ( Table 3 ). In eight of 18 patients, no mutations were identifi ed. We observed identical point mutations in each tumor examined in eight patients. In two of 18 patients, tumors showed different point mutations: in patient 4, codon 184 of exon 5 (GAT) was mutated to TAT in the fi rst tumor, codon 179 of exon 5 (CAT) was mutated to TAT in the second tumor, and codon 253 of exon 7 (CCA) was mutated to ACA in both tumors, and in patient 5, codon 234 of exon 7 (ACA) was mutated to GCA in the second tumor but not in the fi rst tumor. In X-chromosome inactivation analysis, 19 (83%) of 23 patients were informative and the remaining four (ie, patients 2, 7, 10, and 20) noninformative. A concordant pattern of nonrandom X-chromosome inactivation among the synchronous or metachronous cancers was observed in 15 (79%) of 19 informative patients. The remaining four patients demonstrated a random (biallelic) pattern of X-chromosome inactivation in some (patient 1) or all tumors (ie, patients 12, 13, and 16) ( Table 2 ) . Therefore, tumors in 18 (78%, 95% CI = 67% to 98%) of the 23 female patients showed identical X-chromosome inactivation patterns.
Combining the results of LOH studies, TP53 mutation screening analyses, and X-chromosome inactivation data, we demonstrated that the multiple separate tumors in 23 (77%, 95% CI = 62% to 92%) of the 30 patients had identical genetic changes, consistent with monoclonal origin of these separate tumors.
Discussion
The finding of synchronous or metachronous multiple tumors in the same patient is common in lung cancer, with the latter more frequent ( 3 -5 ) . Multiplicity of lung cancers complicates staging and resulted in several revisions of TNM staging systems in recent years that reflect divergent opinions as to whether satellite tumors represented separate primary tumors, local spread of an existing tumor, or distant metastases. The most recent version of the AJCC Cancer Staging Manual (2002) proposes that multiple synchronous tumors should be considered separate primary lung cancers and that each should be staged separately ( 22 ) . As defined by Martini and Melamed ( 7 ), synchronous tumors include tumors of different histological types or two tumors of the same histological type in the separate lobes, with no evidence of lymph node metastases within a common lymph node drainage. The presence of multiple or satellite tumors (excluding involved lymph nodes) within the primary tumor lobe of the lung indicates a locally (Table continues) advanced (T4) lesion in the recent AJCC staging system ( 22 ) . Intrapulmonary ipsilateral tumors in a non-primary tumor lobe or contralateral satellite lesions are classified as metastatic cancers (M1) in the 1997 ( 41 ) and 2002 ( 22 ) versions of the AJCC Cancer Staging Manual rather than separate primary lung cancers, but there is no clarification in terms of lymph node status in comparison to the criteria by Martini and Melamed ( 7 ). In short, there is a lack of clarity and consistency in staging patients with multifocal lung cancer.
Criteria used for staging do not currently incorporate molecular data. Detailed characterization and comparison of genetic changes in multifocal tumors, whether synchronous or metachronous, are potentially useful for ascertaining their clonality and for determining whether they are separate primary lesions or a single Table 2 .
primary cancer with metastases. Such information would simplify staging criteria.
Previous studies of clonality in multifocal lung cancer have produced inconclusive or confl icting results ( 42 -46 ) . We explored the origin of multifocal lung tumors by comparing LOH patterns at several polymorphic microsatellite markers including D3S1766 (3p14 -21), D4S408 (4q33 -34), IFNA (9p21), D9S171 (9p21), D11S970 (11q13), and TP53 (17p13.1) in individual patients. All 30 patients showed LOH in at least one of the six polymorphic microsatellite markers. The number of LOH at the polymorphic microsatellite loci in a single tumor ranged from 1 to 4 markers. The overall frequencies of allelic loss for the informative marker were 21% -52%, which agreed with the frequent molecular changes involved in the lung tumorigenesis observed by others. Our fi nding of concordant LOH patterns between synchronous and metachronous cancers in 26 (87%) of 30 patients provides strong support for a monoclonal origin of these multifocal tumors. This fi nding is also consistent with the observations of Shimizu et al. ( 42 ) . They found that 11 (79%) of 14 cases of multiple synchronous lung tumors were of monoclonal origin using LOH and p53 mutational analysis ( 42 ) . Other studies have shown different genetic profi les in synchronous or metachronous multifocal lung cancers, with the variability in the genetic profi les ranging from 37% to 60% of the patients examined ( 43 -46 ) . This degree of variability does not exclude the possibility of monoclonal origin with subsequent genetic tumoral heterogeneity due to subclonal drifts. In support of this possibility, accumulation of genetic changes associated with tumor progression has been well characterized in many organ systems ( 30 , 34 , 47 -50 ) .
To further address the issue of clonality, tumors from 18 patients were also sequenced for TP53 gene mutations. Although no mutations or identical point mutations were identifi ed in 16 (89%) of the 18 patients, the tumors from patients 4 and 5 showed different point mutations. However, these two patients had identical LOH patterns and X-chromosome inactivation patterns. The fi ndings in these two patients may represent clonal evolution because these separate tumors from the same patient differed only by one point mutation in the three exons examined.
Our series is, to our knowledge, the fi rst to report the use of X-chromosome inactivation analysis to address the origin of multifocal lung tumors. In our study, 18 (78%) of 23 female patients showed concordant X-chromosome inactivation patterns in all the tumors from individual patients. These concordant X-chromosome inactivation patterns also suggest that multiple synchronous or metachronous lung tumors are of clonal origin and represent a single primary lung cancer with subsequent intrapulmonary metastases.
Combining our results of LOH studies, TP53 mutation screening analyses, and X-chromosome inactivation data, we demonstrated that the multiple separate tumors in 23 (77%) of 30 patients had identical genetic changes, consistent with a monoclonal origin of these separate tumors rather than separate independent primary lung tumors. Our fi ndings support the current classifi cation of multifocal lung cancers as advanced-stage cancers (M1, stage IV) rather than separate primary cancers and the use of therapeutic strategies tailored for patients with advanced-stage cancers. Although conventional treatment for patients with stage IV cancer is palliative for most patients, some studies have reported that resection of multiple tumors, when clinically and technically ND  ND  F1  ND  ND  ND  F2  ND  ND  ND  F3  ND  ND  ND  30  N  ND  ND  ND  F1  ND  ND  ND  F2  ND  ND  ND  F3  ND  ND  ND  F4  ND  ND  ND  F5 ND ND ND * Data are the codon modified, the base changes at that codon, and the amino acid change. ND = no mutation detected; N = normal tissue; F1 -F5 = different tumor focus.
feasible, has prolonged the 5-year survival rate for patients with multiple lung cancers ( 51 , 52 ) . Therefore, the presence of multiple synchronous or metachronous tumors should not preclude treatment by surgical resection. Additional clinical data are needed to facilitate the development of rational therapeutic strategies aimed at improving the prognosis of patients with multifocal lung cancers. Further molecular studies including DNA sequencing of greater numbers of patients and strict adherence to morphological subtyping of tumors may provide further insight into the precise origin of multifocal lung cancers. There are several limitations to this retrospective study. The number of cases available for study was relatively small. The tumors analyzed were predominantly adenocarcinomas; therefore, caution is warranted in interpreting our data. Patient selection bias should also be considered. The genetic testing was conducted only on tumors resected from patients who were deemed clinically to be candidates for surgical management. We did not attempt to link genetic alterations with other clinical parameters, such as quantitative exposure to tobacco smoke. We used three different methods for determination of clonality -LOH, TP53 mutations, and X-chromosome inactivation. It was our premise that this combination of tests would suffi ce, and the data we obtained provide strong support for the conclusions we have reached. We acknowledge that other types of molecular studies, such as gene expression profi ling and epigenetic analysis, may provide additional insights into this clinically important question.
In summary, our data indicate that the great majority of multifocal lung cancers have a common clonal origin and represent local and regional intrapulmonary metastasis. Our fi ndings may have relevance in the assignment of proper clinical stage, in estimating prognosis, and in tailoring appropriate therapy.
